Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds

Journal of Neurosciences in Rural Practice

Volumn 3, Issue 1, 2012, Pages 45-50

  Whelan, Paul ^a   Remski, Kimberly ^a  

^a CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Addiction; buprenorphine; detoxification; maintenance; methadone; opiate

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; METHADONE; MU OPIATE RECEPTOR;

COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE SEVERITY; DRUG ABUSE; DRUG COST; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG OVERDOSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; HUMAN; INDIA; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; OPIATE ADDICTION; PRECIPITATED WITHDRAWAL; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SYSTEMATIC REVIEW; TORSADE DES POINTES; TOXIC HEPATITIS;

EID: 84856386075     PISSN: 09763147     EISSN: 09763155     Source Type: Journal    
DOI: 10.4103/0976-3147.91934     Document Type: Review

References (30)

1. Health Protection Agency. Shooting up: Infections among injecting drug users in the United Kingdom 2005. London: Health Protection Agency 2006.
2. Ghodse AH, Sheehan M, Taylor C, Edwards G. Deaths of drug addicts in the United Kingdom 1967-81. Br Med J (Clin Res Ed) 1985;290: 425-8. (Pubitemid 15080969)
3. Parker H, Newcombe R. Heroin use and acquisitive crime in an English community. Br J Sociol 1987;38:331-50.
4. World Health Organization, Department of mental health and substance misuse. Proposal for the inclusion of buprenorphine in the WHO model list of essential medicines. WHO 2004. Available from: http://www.who.int/substance- abuse/activities/buprenorphine-essential-medicines.pdf.[Last accessed: 2011].
5. United Nations Drug Control Programme. Available from: http://www. un.org/Docs/SG/SG-Rpt/ch3c-5.htm. [Last accessed on 2000].
6. United Nations Office on Drugs and Crime. World Drug Report 2009;152-6.\
7. Clinical practice guidelines for management of opioid dependence. Indian Psychiatr Soc 2004.\
8. Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust 1999;170:104-9. (Pubitemid 29060340)
9. Wolff K. Characterization of methadone overdose: clinical considerations and the scientifi c evidence. Ther Drug Monit 2002;24:457-70. (Pubitemid 34857897)
10. Rothman RB, Gorelick DA, Heishman SJ, Eichmiller PR, Hill BH, Norbeck J, et al. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. J Subst Abuse Treat 2000;18:277-81. (Pubitemid 30163033)
11. Mattick R, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003:CD002207.
12. Ray R, Pal H, Kumar R, Maulick P, Mangla R. Post-marketing surveillance of buprenorphine. Pharmacoepidemiol Drug Saf 2004;13;615-9.
13. De S, Jain R, Ray R, Dhawan A, Varghese ST. Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects. Indian J Physiol Pharmacol 2008;52:53-63. (Pubitemid 351820260)
14. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2006:CD002025.
15. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-171, iii-iv.
16. Wolff K, editor. Substance Misuse: Substitution drugs (methadone and buprenorphine) Oxford: Elsevier; 2005.
17. Mégarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ. Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences. Toxicol Rev 2006;25:79-85. (Pubitemid 44379890)
18. Hammersley R, Cassidy MT, Oliver J. Drugs associated with drug-related deaths in Edinburgh and Glasgow, November 1990 to October 1992. Addiction 1995;90:959-65.
19. Auriacombe M, Fatséas M, Dubernet J, Daulouède JP, Tignol J. French fi eld experience with buprenorphine. Am J Addict 2004;13 Suppl 1: S17-28.
20. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005;100:197-205. (Pubitemid 40255377)
21. Smith MY, Bailey JE, Woody GE, Kleber HD. Abuse of buprenorphine in the United States: 2003-2005. J Addict Dis 2007;26:107-11. (Pubitemid 47367833)
22. Winstock AR, Lea T, Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. Int J Drug Policy 2008;19:450-8.
23. Cowan A, Lewis JW, editors. Buprenorphine: combating drug abuse with a unique opioid. Chichester: Wiley-Liss; 1995.
24. Department of Health. Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health; 2007.
25. Krantz MJ, Rowan SB, Schmittner J, Bucher Bartelson B. Physician awareness of the cardiac effects of methadone: results of a national survey. J Addict Dis 2007;26:79-85.
26. Ganguly K. The pattern and process of drug and alcohol use in India. ICMR Bull 2008; Available from: http://www.icmr.nic.in/bulletin/english/2008/ bulljan-mar08.pdf. [Last accessed on 2008].
27. Taylor D, Paton C, Kerwin R. The Maudsley prescribing Guidelines 9th ed. London: Informa Healthcare; 2007.
28. Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, et al. Methadone versus buprenorphine in pregnant addicts: a doubleblind, double-dummy comparison study. Addiction 2006;101:275-81. (Pubitemid 43351601)
29. Ball J, Ross A. The effectiveness of methadone maintenance treatment: Patients, programs, services and outcome. New York: Springer-Verlag; 1991.
30. National Institute of Health and Clinical Excellence. Drug misuse: psychosocial interventions: NICE guideline 51. Available from: http://guidance.nice.org.uk/CG51. [Last accessed in 2011].